MAP3K6 functions in compensatory feedback signaling during clinical interventions featuring use of the VEGF-A inhibitor bevacizumab.
Fuente:
Zenodo
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Format: | Recurso digital |
| Veröffentlicht: |
Zenodo
2025
|
| Online-Zugang: | |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| _version_ | 1866901203983532032 |
|---|---|
| author | Mamoor, Shahan |
| author_facet | Mamoor, Shahan |
| contents | <p>Clinical interventions featuring administration of a vascular endothelial growth factor inhibitor (bevacizumab) will generally universally exhibit rebound or compensatory growth factor signaling occurring through specific activation of kinase and phosphatase signal transduction enzymes. Compensatory growth factor signaling enabled by kinase or phosphatase activation supports resistance during the treatment of cancer in humans. We describe here activation of the MAP kinase MAP3K6 in humans following treatment with bevacizumab (Avastin). </p> <p> </p> <p> </p> |
| format | Recurso digital |
| id | zenodo_https___doi_org_10_5281_zenodo_18007959 |
| institution | Zenodo |
| language | |
| publishDate | 2025 |
| publisher | Zenodo |
| record_format | zenodo |
| spellingShingle | MAP3K6 functions in compensatory feedback signaling during clinical interventions featuring use of the VEGF-A inhibitor bevacizumab. Mamoor, Shahan <p>Clinical interventions featuring administration of a vascular endothelial growth factor inhibitor (bevacizumab) will generally universally exhibit rebound or compensatory growth factor signaling occurring through specific activation of kinase and phosphatase signal transduction enzymes. Compensatory growth factor signaling enabled by kinase or phosphatase activation supports resistance during the treatment of cancer in humans. We describe here activation of the MAP kinase MAP3K6 in humans following treatment with bevacizumab (Avastin). </p> <p> </p> <p> </p> |
| title | MAP3K6 functions in compensatory feedback signaling during clinical interventions featuring use of the VEGF-A inhibitor bevacizumab. |
| url | https://doi.org/10.5281/zenodo.18007959 |